Physician profile
Bridget Jones
NPI 1790040533
$13,707.67
in general payments reported to CMS, 2019-2025
61 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $743 · 2021: $1,563 · 2022: $1,659 · 2023: $3,394 · 2024: $2,189 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,160 · Travel and Lodging: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,160.05 |
| Travel and Lodging | $759.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.35 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $778.60 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Intuitive Surgical, INC. | $759.86 | 2023 | Da Vinci Surgical System |
| Sk Life Science, INC. | $752.01 | 2020-2025 | |
| Pfizer INC. | $717.31 | 2019-2025 | |
| Ucb, INC. | $658.15 | 2019-2025 | Briviact, Nayzilam |
| Lundbeck LLC | $634.41 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $633.20 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $616.43 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $536.48 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $529.17 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $361.61 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $341.02 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Otsuka America Pharmaceutical, INC. | $329.58 | 2022-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $300.29 | 2023-2025 | Xeomin, Inbrija, Ampyra |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $279.74 | 2022-2025 | Qelbree, Apokyn, Xadago |
| Biogen, INC. | $245.17 | 2019-2025 | Leqembi, Skyclarys |
| Sunovion Pharmaceuticals INC. | $244.16 | 2019 | |
| Csl Behring | $226.73 | 2019-2025 | Hizentra |
| Acorda Therapeutics, INC | $221.80 | 2019-2023 | Inbrija |
| Avanir Pharmaceuticals, INC. | $194.74 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $179.52 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $177.85 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $174.18 | 2019-2025 | Ongentys, Rytary, Crexont |
| Medtronic, INC. | $172.41 | 2021-2022 | |
| Argenx US, INC. | $163.55 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $162.53 | 2020-2025 | Uplizna |
| Genentech USA, INC. | $152.03 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $145.00 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.16 | 2022 | |
| Adamas Pharmaceuticals, INC. | $124.25 | 2019 | |
| Mallinckrodt Hospital Products INC. | $104.85 | 2021-2023 | Acthar |
| Corium, LLC | $104.16 | 2022-2023 | Adlarity |
| Neurelis, INC. | $103.21 | 2023-2025 | Valtoco |
| Eisai INC. | $100.89 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.50 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $89.49 | 2019-2023 | |
| Axsome Therapeutics, INC. | $89.16 | 2025 | Symbravo |
| Allergan, INC. | $79.73 | 2020 | |
| Emd Serono, INC. | $79.20 | 2020-2025 | |
| Kyowa Kirin, INC. | $70.15 | 2023-2025 | Nourianz |
| Greenwich Biosciences, INC. | $63.01 | 2019-2020 | |
| Assertio Therapeutics, INC. | $57.57 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $56.27 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $54.95 | 2020 | |
| Grifols USA, LLC | $47.83 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $44.42 | 2023-2024 | Aptiom |
| Horizon Therapeutics Plc | $35.70 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $35.49 | 2025 | |
| Xeris Pharmaceuticals, INC. | $33.66 | 2022 | |
| Mylan Specialty L.P. | $32.88 | 2023 | Glatiramer Acetate |
| Convatec INC. | $29.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $27.47 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.61 | 2025 | Amvuttra |
| Si-Bone, INC. | $24.49 | 2023 | |
| Medline Industries LP | $24.18 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.71 | 2022 | |
| Boston Scientific Corporation | $20.09 | 2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $14.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.16 | 2020 | |
| Celgene Corporation | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.